• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Providing unlimited, immediate access to opioid agonist therapy to people with opioid use disorders could save billions and improve outcomes

byCaitlyn HuiandDeepti Shroff Karhade
November 21, 2017
in Chronic Disease, Emergency, Infectious Disease, Psychiatry, Public Health
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Unlimited, immediate access to opioid agonist treatment (OAT) was shown, through a simulation, to be more cost effective compared to the Observed California care and California guideline treatment strategies.

2. Simulation results also indicated that unlimited, immediate access to OAT would increase quality of life years (QALY) gained and other health outcomes, such as HIV incidence, compared to current standards of care.

Evidence Rating Level: 2 (Good)

Study Rundown: While the rates of opioid use have dramatically increased in the United States, there has not been a parallel increase in opioid treatment to reflect the rising rates of this usage disorder. Currently, California has the highest volume of persons with an opioid use disorder in the United States. Despite these numbers many patients are not receiving the international evidence-based standard of care for opioid use—initial, unlimited access to OAT. The authors of this study aimed to assess the effectiveness of unlimited OAT, both in terms of health and cost-effectiveness outcomes, compared to the current standard of care in California’s publicly funded treatment facilities. Through a model-based cost-effectiveness analysis, it was observed that unlimited and immediate OAT access is more cost effective and improves outcomes compared to traditional care. This study has several limitations. First, the study was restricted solely to publically funded opioid use disorder treatment and did not include office-based settings. Additionally, the authors generated limited data that could be applied to evaluate accessibility of direct-acting antiviral therapy among the study population. Overall, the results of the study suggest that switching to an initial, unlimited OAT model of care could save significant costs and improve health outcomes for opioid use disorder patients in California.

Click to read the study in the Annals of Internal Medicine

Relevant Reading: A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence

In-Depth [retrospective cohort]: In order to assess the effectiveness of initial, unlimited OAT, the authors conducted a model-based cost-effectiveness analysis. Primary outcomes included mortality, HIV seroconversion, and incarceration. The data was retrieved from linked population-level administrative databases between the years of 2006-2010. With respect to outcomes, the authors observed that immediate access to OAT for all treatment patients was $78 257 less expensive compared to current standard of care. Furthermore, patients extended QALY by 0.42 when accessing immediate, unlimited OAT. The HIV incidence per 100 person-years for the immediate OAT strategy was 1.37, with a survival of 53.6%, compared to 1.64 and a survival of 50.9% for the observed California care and 2.20 and 49.3% for the California guideline. The sensitivity analysis, which consisted of 2000 simulations, indicated 99.6% sensitivity that the initial OAT strategy would reduce cost and improve health outcomes.

RELATED REPORTS

Reinfection with hepatitis C virus is highest immediately after treatment in patients on opioid agonist therapy

Prenatal exposure to opioids and its potential associations with subsequent academic performance

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: drug abuseopioid epidemicopioidssubstance abuse
Previous Post

Cluster analysis identifies phenotype groups for atrial fibrillation with unique clinical outcomes

Next Post

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Reinfection with hepatitis C virus is highest immediately after treatment in patients on opioid agonist therapy

August 25, 2022
Characteristic differences between young children and adolescents who die by suicide
Obstetrics

Prenatal exposure to opioids and its potential associations with subsequent academic performance

July 25, 2022
#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication
StudyGraphics

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

June 11, 2022
#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia
StudyGraphics

#VisualAbstract: Canakinumab treatment did not reduce pain to clinical significance but shows anti-inflammatory effects in children and young adults with sickle cell anemia

May 4, 2022
Next Post
Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

Gardasil vaccine demonstrates immunogenic response at 10-year follow-up

Development of a risk index for colorectal cancer screening

Study suggests testing certain protein combinations can enhance sensitivity of fecal immunochemical test used in colorectal cancer screenings

Ultrasound screening for AAAs has no effect on all-cause mortality

2 Minute Medicine Rewind November 20, 2017

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options